{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/management/primary-prevention-of-cvd/","result":{"pageContext":{"chapter":{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD","depth":2,"htmlHeader":"<!-- begin field a97af74f-5911-4b9b-a600-a7810088d09b --><h2>Scenario: Antiplatelet treatment for primary prevention of cardiovascular disease (CVD)</h2><!-- end field a97af74f-5911-4b9b-a600-a7810088d09b -->","summary":"Covers when to prescribe antiplatelet drugs in a person who has not had a prior cardiovascular event.","htmlStringContent":"<!-- begin item 7a28a618-24e8-4b82-8deb-a7810088cf10 --><!-- begin field 7c9060a0-481c-4aed-955a-acbc01567735 --><p>From age 16 years onwards.</p><!-- end field 7c9060a0-481c-4aed-955a-acbc01567735 --><!-- end item 7a28a618-24e8-4b82-8deb-a7810088cf10 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"4eacbf82-2f84-5c89-8bec-e1e3d4863506","slug":"when-to-prescribe-antiplatelet-treatment-primary-prevention","fullItemName":"When to prescribe antiplatelet treatment (primary prevention)","depth":3,"htmlHeader":"<!-- begin field 7bd5c3cb-aa50-4284-86bd-a7810088d0a0 --><h3>When should antiplatelet treatment be prescribed for primary prevention of cardiovascular disease?</h3><!-- end field 7bd5c3cb-aa50-4284-86bd-a7810088d0a0 -->","summary":null,"htmlStringContent":"<!-- begin item 345c1ee7-0b31-40f5-83c0-a7810088d0a0 --><!-- begin field 2aaa4379-0b90-4f22-acd4-a7810088d0a0 --><ul><li><strong>Do not routinely prescribe antiplatelet treatment for the primary prevention of cardiovascular disease (CVD)</strong>.</li><li>Consider prescribing aspirin in people with a high risk of stroke or myocardial infarction. See <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/management/cvd-risk-assessment/#risk-assessment-procedure\">CVD risk assessment</a>  for more information.<ul><li>In deciding whether to treat or not treat with aspirin consider the following:<ul><li>Aspirin is not licensed for the primary prevention of CVD.</li><li>People may be able to reduce their CVD risk through other means such as stopping smoking or starting a statin. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li><li>There is limited evidence of benefit even in people with multiple risk factors and there is a risk of harm.</li></ul></li></ul></li><li><strong>If aspirin is being considered, discuss the likely benefits (reduced CVD risk) and risks (such as gastrointestinal bleeding) with the person.</strong><ul><li>For people at risk of developing dyspepsia, or who have developed dyspepsia after starting treatment, see the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/#preventing-dyspepsia\">preventing dyspepsia</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/#managing-antiplatelet-induced-dyspepsia\">Managing antiplatelet-induced dyspepsia</a>, in the scenario <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/\">Secondary prevention of CVD</a>.</li></ul></li></ul><!-- end field 2aaa4379-0b90-4f22-acd4-a7810088d0a0 --><!-- end item 345c1ee7-0b31-40f5-83c0-a7810088d0a0 -->","subChapters":[{"id":"20f53cde-3f64-5741-8fd9-9f1018646ef5","slug":"basis-for-recommendation-cf0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1e06e03c-a0be-4d00-96ca-a7810088d0a4 --><h4>Basis for recommendation</h4><!-- end field 1e06e03c-a0be-4d00-96ca-a7810088d0a4 -->","summary":null,"htmlStringContent":"<!-- begin item cf0d5319-1515-48ee-a411-a7810088d0a4 --><!-- begin field e1db8073-f781-4ab5-98f5-a7810088d0a4 --><p>These recommendations are based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Risk estimation and the prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2017</a>], the European Society of Cardiology (ESC) <em>2016 European guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>], an ESC position paper <em>Aspirin therapy in primary cardiovascular disease prevention</em><em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Halvorsen, 2014</a>]  the British and Irish Hypertension Society (BIHS) <em>Statement on the use of aspirin </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BIHS, 2017</a>], National Institute for Health and Care Excellence (NICE) guidelines <em>Type 1 diabetes in adults: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016c</a>] and <em>Type 2 diabetes in adults: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2017</a>], and a Medicines and Healthcare products Regulatory Agency (MHRA) drug safety update <em>Aspirin: not licensed for primary prevention of thrombotic vascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">MHRA, 2009</a>]. </p><ul><li>Aspirin use, in general, should be restricted to people with a prior history of cardiovascular disease (CVD) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BIHS, 2017</a>]. <ul><li>Aspirin may be considered beneficial for primary prevention if an individual’s future risk of stroke or heart attack is higher than average.</li><li>An accurate quantitative assessment of CVD risk is essential before prescribing aspirin for individuals in the primary prevention of CVD, where the evidence for benefit versus harm is very limited.</li></ul></li><li>Antiplatelet therapy is not recommended in people who do not have CVD, due to the increased risk of major bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>]. <ul><li>In a systematic review of six trials (n = 95,000), which compared the long-term use of aspirin vs control in people without overt CV or cerebrovascular disease, a risk reduction from 0.57% per year to 0.51% per year of serious vascular events was found, and major gastrointestinal (GI) and extracranial bleeds increased by 0.03% per year. The risk of vascular mortality was not changed by treatment with aspirin.</li><li>In a Japanese study (n = 14,464), people aged 60–85 years with hypertension, dyslipidaemia or diabetes mellitus were randomized to treatment with 100 mg aspirin or placebo. The 5-year cumulative primary outcome event rate (death from CV causes) was not significantly different between the groups, but treatment with aspirin significantly increased the risk of extracranial haemorrhage requiring transfusion or hospitalization (P = 0.004).</li><li>However, in a position paper, an ESC working group suggested that aspirin should be considered in the primary prevention of CVD in people at a high risk of major cardiovascular events — more than 2 per 100 subject-years, provided there is no clear evidence of increased risk of bleeding (GI bleeding or peptic ulcer disease, no concurrent use of other medications that increase bleeding risk) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Halvorsen, 2014</a>]. <ul><li>In the absence of such conditions, people with a 10-year risk of major CV of more than 20% should be given low-dose aspirin, and people with a risk 10–20% should be considered potentially eligible.</li></ul></li></ul></li><li>NICE guidelines on diabetes mellitus advise that aspirin should not be offered to people with diabetes, if they do <em>not</em> have CVD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2017</a>].  </li><li>The Medicines and Healthcare products Regulatory Agency (MHRA) recommends that if aspirin is used for primary prevention (off-label use), the balance of benefits and risks should be considered for each individual [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">MHRA, 2009</a>].</li></ul><!-- end field e1db8073-f781-4ab5-98f5-a7810088d0a4 --><!-- end item cf0d5319-1515-48ee-a411-a7810088d0a4 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}